From the Corporate World to Venture Capital
Executive Summary
In making the move from the corporate device world, i.e., Boston Scientific to venture capital, at SVLS, a leading venture firm, David Milne has found the two worlds--while critically linked--are strikingly different.
You may also be interested in...
US FDA’s Anti-Misinformation Campaigns Look Safer After Supreme Court Oral Arguments
FDA’s efforts to tackle misinformation may face fewer legal obstacles moving forward, following oral arguments at the Supreme Court on a case that could have broad ramifications for how the government communicates public health information.
The Dog That Didn’t Bark: ODAC Gives Nod To Three Products Despite Negative FDA Reviews
Oncologic Drugs Advisory Committee was swayed by views of its disease area experts in favorably reporting out Geron’s imetelstat for myelodysplastic syndromes and supplemental applications for the CAR-T products Carvykti and Abecma in earlier lines of multiple myeloma.
Demi Moore’s Wonderbelly Antacids Investment Lands Supporting Role In Her Promotional Posts
Wonderbelly Antacids “free from” ad claims work but failing to disclose Demi Moore is an investor in her promotions doesn’t, NAD says. Dakota Nutrition fails again on NAD’s test of its testing for elderberry in its supplements.